Immunome Inc IMNM:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 5:35 PM EDT19.32
-0.49 (-2.47%)
-0.49 (-2.47%)Volume
29,729
Close
19.81
+0.47 (+2.43%)
+0.47 (+2.43%)Volume
1,212,452
52 week range
7.96 - 27.65
- Open19.30
- Day High19.84
- Day Low18.89
- Prev Close19.34
- 52 Week High27.65
- 52 Week High Date02/04/26
- 52 Week Low7.96
- 52 Week Low Date07/15/25
Latest On Immunome Inc
Key Stats
- Market Cap2.243B
- Shares Out113.25M
- 10 Day Average Volume1.39M
- Dividend-
- Dividend Yield-
- Beta2.07
Latest On Immunome Inc
KEY STATS
- Open19.30
- Day High19.84
- Day Low18.89
- Prev Close19.34
- 52 Week High27.65
- 52 Week High Date02/04/26
- 52 Week Low7.96
- 52 Week Low Date07/15/25
- Market Cap2.243B
- Shares Out113.25M
- 10 Day Average Volume1.39M
- Dividend-
- Dividend Yield-
- Beta2.07
RATIOS/PROFITABILITY
- EPS (TTM)-2.36
- P/E (TTM)-8.38
- Fwd P/E (NTM)-8.69
- EBITDA (TTM)-226.35M
- ROE (TTM)-50.14%
- Revenue (TTM)4.015M
- Gross Margin (TTM)-
- Net Margin (TTM)-5,593.85%
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/04/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREImmunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a...
Clay Siegall Ph.D.
Chairman of the Board, President, Chief Executive Officer
Max Rosett
Chief Financial Officer
Phil Tsai Ph.D.
Chief Technical Officer
Sandra Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Address
18702 N. CREEK PARKWAY, SUITE 100
Bothell, WA
98011
United States